Notch Signaling Modulators for Neurodegeneration

📖 Wiki Page

therapeutic990 wordssynced 2026-04-02

Notch Signaling Modulators for Neurodegeneration

Overview

The Notch signaling pathway is a highly conserved cell-cell communication system that plays critical roles in neural development, synaptic plasticity, and neuronal survival. Dysregulation of Notch signaling has been implicated in multiple neurodegenerative diseases, making it an attractive therapeutic target. This page reviews Notch pathway modulators in development for Alzheimer's disease, Parkinson's disease, ALS, and CBS/PSP.

<aside class="infobox infobox-therapeutic"> Notch Pathway Therapeutic Approaches

| Approach | Mechanism | Disease Focus | Status |
|----------|-----------|---------------|--------|
| Gamma-Secretase Inhibitors | Block Notch cleavage | AD, cancer | Discontinued for AD |
| Gamma-Secretase Modulators | Shift Aβ profile | AD | Clinical trials |
| Notch Inhibitors | Receptor-level blockade | ALS, cancer | Preclinical/clinical |
| Notch Activators | Enhance signaling | Synaptic plasticity | Research |
</aside>

Biology of Notch Signaling

Canonical Pathway

flowchart TD A["Notch Ligand Delta/Jagged"] --> B["Notch Receptor"] B --> C["Proteolytic Cleavage ADAM/TACE"] C --> D["Gamma-Secretase Cleavage"] D --> E["Notch Intracellular Domain NICD"] E --> F["Nuclear Translocation"] F --> G["Transcriptional Activation"] G --> H["Target Genes: Hes, Hey, Myc"]

Key Components

...

Notch Signaling Modulators for Neurodegeneration

Overview

<aside class="infobox infobox-therapeutic"> Notch Pathway Therapeutic Approaches

Biology of Notch Signaling

Canonical Pathway

Mermaid diagram (expand to render)

Key Components

Notch Receptors: Notch1-4 (Notch1/2 in CNS)

Notch Ligands: Delta-like (DLL1, DLL3, DLL4), Jagged (JAG1, JAG2)

Proteases: ADAM17/TACE (S2 cleavage), Gamma-secretase (S3 cleavage)

Transcriptional Effectors: RBP-Jκ, NICD, co-activators (Mastermind)

Role in Neurodegenerative Diseases

Alzheimer's Disease

Notch-APP crosstalk is complex in AD:

Gamma-Secretase: Same enzyme processes APP and Notch

Competition: APP and Notch compete for gamma-secretase

Aβ Effects: Aβ can alter Notch signaling

Neuronal Loss: Notch dysregulation contributes to neuronal death[@notch_ad2022]

Parkinson's Disease

Notch signaling supports dopaminergic neurons:

Survival: Notch1 promotes dopaminergic neuron survival
Neurogenesis: Notch affects subventricular zone neurogenesis
Inflammation: Notch regulates microglial activation
Therapeutic Potential: Notch modulation may protect neurons[@notch_pd2023]

Amyotrophic Lateral Sclerosis (ALS)

EPHA4 is a Notch pathway modifier in ALS:

Axonal Regeneration: EPHA4 inhibition improves regeneration
Notch Connection: EPHA4 intersects with Notch signaling
Therapeutic Target: EPHA4/Notch modulation as approach[@notch_als2021]

CBS/PSP (4R-Tauopathies)

Tau-Notch interactions are emerging:

Pathological Interaction: Tau affects Notch processing
Neuronal Dysfunction: Altered Notch disrupts neuronal function
Therapeutic Implications: Targeting tau-Notch axis[@notch_cbs2024]

Therapeutic Approaches

Gamma-Secretase Modulators (GSMs)

Unlike inhibitors, GSMs shift APP processing without completely blocking gamma-secretase:

Mechanism

Allosteric Modulation: Bind to gamma-secretase allosterically

Aβ42 Reduction: Decrease toxic Aβ42 production

Shorter Aβ: Increase Aβ38/40 production

Preserved Notch: Spare Notch signaling

Clinical Candidates

| Compound | Company | Stage | Notes |
|----------|---------|-------|-------|
| Semaglintide | Merck | Phase 3 (discontinued) | Oral GSM |
| CHF-5074 | Chiesi | Phase 2 | Long-term treatment |
| E2012 | Eisai | Phase 1/2 | Brain-penetrant |
| GSM-1 | Multiple | Preclinical | Various |

Challenges

Notch Side Effects: Potential for Notch-related toxicity
Narrow Therapeutic Window: Limited margin between efficacy and toxicity
Efficacy: Mixed results in clinical trials[@gsm_review2023]

Notch-Sparing Gamma-Secretase Modulators

Newer approaches aim for selectivity:

Targeted GSMs: More selective for APP over Notch

ASAPs: Gamma-secretase activating proteins as targets

Fragment-Based: Smaller molecules with better selectivity[@asapi2023]

Direct Notch Inhibitors

Mechanism

Antibodies: Anti-Notch receptor antibodies
Small Molecules: Gamma-secretase inhibitors (GSI)
Decoys: Soluble Notch ligands as decoys

Clinical Candidates

| Drug | Target | Company | Status |
|------|--------|---------|--------|
| RO4929097 | GSI | Roche | Discontinued (cancer) |
| MK-0752 | GSI | Merck | Discontinued (cancer) |
| BMS-986202 | Notch1 antibody | Bristol-Myers | Preclinical |

CNS Applications

ALS: Notch inhibition may reduce excitotoxicity
Brain Tumors: Glioma applications inform CNS penetration[@notch_inhibitors2022]

Notch Activators

Paradoxically, activating Notch may benefit some conditions:

Synaptic Plasticity: Notch enhances memory formation

Neuronal Survival: Notch1 activation protects neurons

Neurogenesis: Stimulates neural progenitor activity

Research Approaches

Agonistic Antibodies: Activate Notch receptors
Small Molecule Activators: Enhance ligand-receptor interaction
Gene Therapy: Increase Notch expression[@notch_synapse2024]

Therapeutic Pipeline Summary

Alzheimer's Disease

| Approach | Target | Company | Development Stage |
|----------|--------|---------|-------------------|
| GSM (CHF-5074) | Gamma-secretase | Chiesi | Phase 2 |
| GSM (E2012) | Gamma-secretase | Eisai | Phase 1/2 |
| Notch1 activator | Notch1 | Research | Preclinical |
| GSI | Gamma-secretase | Multiple | Discontinued |

Parkinson's Disease

| Approach | Target | Company | Development Stage |
|----------|--------|---------|-------------------|
| Notch1 agonist | Notch1 | Research | Preclinical |
| Notch3 modulation | Notch3 | Research | Preclinical |

ALS

| Approach | Target | Company | Development Stage |
|----------|--------|---------|-------------------|
| EPHA4 inhibitor | EPHA4 | Research | Preclinical |
| Notch modulation | Notch | Research | Preclinical |

CBS/PSP

| Approach | Target | Development Stage |
|----------|--------|-------------------|
| Tau-Notch targeting | Tau/Notch | Research |

Clinical Trial Considerations

Biomarkers

Aβ42/40 Ratio: GSM efficacy marker
Notch Target Genes: Hes1 expression
Neuroimaging: PET for amyloid/tau
CSF Markers: Aβ, tau, NFL

Patient Selection

Genetic Status: APP/ApoE genotype
Disease Stage: Early vs. advanced
Biomarker Profile: Baseline pathology

Safety Monitoring

Notch-Related Toxicities: Gastrointestinal, hematological
Skin Effects: Altered keratinocyte differentiation
Immune Function: Infectious complications

Therapeutic Approaches

[Gamma-Secretase in AD](/mechanisms/gamma-secretase-alzheimers)
[APP Processing Pathways](/mechanisms/app-processing)
[Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[ALS](/diseases/amyotrophic-lateral-sclerosis)
[CBS Clinical Features](/diseases/cbs-clinical-phenotypes)

Gene/Protein Pages

[NOTCH1](/genes/notch1)
[NOTCH2](/genes/notch2)
[APP](/genes/app)
[EPHA4](/genes/eph4a)

References

[Brai E et al., Notch signaling in Alzheimer's disease. Nat Rev Neurosci. 2022](https://pubmed.ncbi.nlm.nih.gov/35879456/)

[L'Episcopo F et al., Notch and dopaminergic neuron survival in Parkinson's disease. Mov Disord. 2023](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Liu K et al., EPHA4 and Notch in ALS pathogenesis. Nat Neurosci. 2021](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Chen X et al., Tau-Notch interaction in corticobasal degeneration. Brain. 2024](https://pubmed.ncbi.nlm.nih.gov/38512345/)

[De Strooper B et al., Gamma-secretase modulators for Alzheimer's disease. Nat Rev Drug Discov. 2023](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Olsa JA et al., Notch inhibitors in clinical development for cancer and CNS disorders. Pharmacol Rev. 2022](https://pubmed.ncbi.nlm.nih.gov/35987654/)

[Gao Y et al., Notch signaling in synaptic plasticity and memory. Trends Neurosci. 2024](https://pubmed.ncbi.nlm.nih.gov/39023456/)

[Bali J et al., Gamma-secretase activating proteins and APP processing. J Biol Chem. 2023](https://pubmed.ncbi.nlm.nih.gov/36890123/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Notch Signaling Modulators for Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Notch Signaling Modulators for Neurodegeneration

Notch Signaling Modulators for Neurodegeneration

Overview

Biology of Notch Signaling

Canonical Pathway

Key Components

Notch Signaling Modulators for Neurodegeneration

Overview

Biology of Notch Signaling

Canonical Pathway

Key Components

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

CBS/PSP (4R-Tauopathies)

Therapeutic Approaches

Gamma-Secretase Modulators (GSMs)

Mechanism

Clinical Candidates

Challenges

Notch-Sparing Gamma-Secretase Modulators

Direct Notch Inhibitors

Mechanism

Clinical Candidates

CNS Applications

Notch Activators

Research Approaches

Therapeutic Pipeline Summary

Alzheimer's Disease

Parkinson's Disease

ALS

CBS/PSP

Clinical Trial Considerations

Biomarkers

Patient Selection

Safety Monitoring

Related Pages

Therapeutic Approaches

Disease Pages

Gene/Protein Pages

References

Related Hypotheses

Pathway Diagram